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The glycosaminoglycan heparan sulfate (HS), present at the surface of most
cells and ubiquitous in extracellular matrix, binds many soluble extracellular
signalling molecules such as chemokines and growth factors, and regulates
their transport and effector functions. It is, however, unknown whether
upon binding HS these proteins can affect the long-range structure of HS.
To test this idea, we interrogated a supramolecular model system, in which
HS chains grafted to streptavidin-functionalized oligoethylene glycol mono-
layers or supported lipid bilayers mimic the HS-rich pericellular or
extracellular matrix, with the biophysical techniques quartz crystal micro-
balance (QCM-D) and fluorescence recovery after photobleaching (FRAP).
We were able to control and characterize the supramolecular presentation of
HS chains—their local density, orientation, conformation and lateral mobi-
lity—and their interaction with proteins. The chemokine CXCL12a (or SDF-
1a) rigidified the HS film, and this effect was due to protein-mediated cross-
linking of HS chains. Complementary measurements with CXCL12amutants
and the CXCL12g isoform provided insight into the molecular mechanism
underlying cross-linking. Fibroblast growth factor 2 (FGF-2), which has
three HS binding sites, was also found to cross-link HS, but FGF-9, which has
just one binding site, did not. Based on these data, we propose that the ability
to cross-link HS is a generic feature of many cytokines and growth factors,
which depends on the architecture of their HS binding sites. The ability to
change matrix organization and physico-chemical properties (e.g. permeability
and rigidification) implies that the functions of cytokines and growth factors
may not simply be confined to the activation of cognate cellular receptors.1. Background
Heparan sulfate (HS) is a linear polysaccharide made of variably sulfated repeat-
ingdisaccharideunits.Attached to extracellularmatrix or cell-surfaceproteins (HS
proteoglycans,HSPGs), it pervades the intercellular space ofmany tissues and the
periphery of virtually all mammalian cells. HS binds many soluble extracellular
signalling molecules such as growth factors and chemokines, and these inter-
actions are known to be important for various physiological and pathological
processes [1–4] including organogenesis and growth control [5,6], cell adhesion
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[10] and interactions with pathogens [11].
Past studies have revealed how HS–protein interactions
determine protein function. For example, HS (as well as the
highly sulfated analog heparin) plays a role in the specificity
and control of the engagement of fibroblast growth factors
(FGFs) with their cell-surface receptors, through the formation
of stable ternary complexes [12], thus modulating cell signal-
ling. The binding of chemokines to HS in the extracellular
space, on the other hand, enables the formation of chemokine
gradients [13], thus providing directional cues and guiding
the migration of appropriate cells in the context of their
inflammatory, developmental and homeostatic functions.
By contrast, very little is known about the effect of signal-
ling proteins on HS and HSPGs. HS chains are typically a
few tens of nanometres in length [14] and, thus, possess mul-
tiple binding sites enabling simultaneous binding of several
proteins [15]. These interactions will influence the molecular
structure of individual HS chains. Moreover, they may also
profoundly affect the supramolecular organization of HS in
the extracellular space. Such long-range effects have hitherto
been difficult to test, because of the lack of appropriate
structural and biochemical methods.
Here, we demonstrate that several soluble extracellular
signalling proteins can effectively cross-link HS. To this end,
we developed an in vitro binding assay that is based on films
of surface-grafted HS chains, as a well-defined model of
HS-rich pericellular or extracellular matrix [7], and a combi-
nation of two biophysical analysis techniques: quartz crystal
microbalance (QCM-D) and fluorescence recovery after photo-
bleaching (FRAP). These techniques provide insight into the
binding of proteins to the HS film, and the concomitant
changes in film morphology and HS chain mobility. Through
the analysis of a set of proteins and their mutants—including
chemokines, cytokines and growth factors—with this assay,
we identify molecular features that determine the HS cross-
linking propensity of extracellular signalling proteins. The abil-
ity to cross-link, and thus to change matrix organization and
physico-chemical properties, implies that the functions of
these proteins may not simply be confined to the activa-
tion of cognate cellular receptors, and we discuss possible
physiological implications.2. Material and methods
2.1. Buffer
The working buffer used for all measurements contained
10 mM HEPES (Fisher, Illkirch, France) at pH 7.4 and 150 mM
NaCl (Sigma-Aldrich, Saint-Quentin Fallavier, France).2.2. Heparan sulfate and proteins
The HS polysaccharide derived from porcine intestinal mucosa
(Celsus Laboratories, Cincinnati, OH, USA) was found to have
an average molecular weight of 12 kDa and a polydispersity of
1.6 [16]. Size-uniformHS oligosaccharides from hexasaccharide
(degree of polymerization, dp6) to dodecasaccharide (dp12)
were derived from this source, as previously described [17].
HS was conjugated with biotin through an oligoethylene
glycol (OEG) linker of approximately 1 nm length, site-specifically attached to the reducing end by oxime ligation. In
contrast to the conventionally used hydrazone ligation, oxime
ligation produces conjugates that are stable for many weeks
in aqueous solution [18]. HS conjugates were stored at a
concentration of 10 mg ml21 at 2208C until further use.
Recombinant CXCL12a (amino acids 1 to 68; 8.1 kDa) was
prepared as previously described [19]. A truncated CXCL12a
construct (amino acids 5 to 67; 7.4 kDa [20]) was produced
by solid-phase peptide synthesis, as previously reported
[4,15]. An I55C/L58C mutant of CXCL12a with reduced
dimerization propensity (‘partial monomer’) was prepared
as previously described [21]. An L36C/A65C mutant of
CXCL12a in which the introduced cysteines promote the for-
mation of dimers (‘locked dimer’) was prepared, as described
in Veldkamp et al. [22]. The cDNA of murine CXCL12g was
inserted in a pET-17b vector (Novagen, Merck Chemical Ltd.,
Nottingham, UK) between NdeI and SpeI restriction sites,
checked by DNA sequencing, and the protein (11.6 kDa) was
produced by recombinant expression in Escherichia coli strain
BL21 Star DE3, as previously reported [23]. Interferon (IFN)g
(17 kDa) was produced by recombinant expression in E. coli
strain BL21 Star DE3 using a pET-11a vector (Novagen), as pre-
viously reported [24]. Recombinant FGF-2 (18 kDa) and FGF-9
(26 kDa) were obtained by expression in C41 E. coli cells using
pET-14b and pET-M11 for vectors (Novagen), respectively, as
described by Xu et al. [25].
Lyophilized streptavidin (SAv), fluorescently labelled SAv
(fl-SAv; with atto565) and bovine serum albumin (BSA) were
obtained from Sigma-Aldrich. All proteins were stored in
working buffer at 2208C until further use. Thawed protein
solutions were used within 5 days.2.3. Surfaces and surface funtionalization with a biotin-
displaying and otherwise inert background
QCM-D sensors with gold (QSX301) and silica (QSX303)
coatings (Biolin Scientific, Va¨stra Fro¨lunda, Sweden) were
used as is. Glass coverslips (24  24 mm2; Menzel-Gla¨ser,
Braunschweig, Germany) for FRAP assays were cleaned by
immersion in freshly prepared piranha solution (i.e. a 1 : 3
(v/v) mixture of H2O2 (Fisher Scientific) and concentrated
H2SO4 (Sigma-Aldrich)) for 1 h, rinsing with ultrapure
water and blow-drying with N2. All substrates were exposed
to UV/ozone (Jelight Company, CA, USA) for 10 min prior
to use.
Gold surfaces were functionalized with biotin-displaying
monolayers of OEG as previously described [7]. Briefly, the
gold-coated surfaces were immersed overnight in an ethan-
olic solution of OEG disulfide and biotinylated OEG thiol
(Polypure, Oslo, Norway), at a total concentration of 1 mM
and a molar ratio of thiol equivalents of 999 : 1.
Silica (for QCM-D) and glass (for FRAP) surfaces were
functionalized with biotin-displaying supported lipid bilayers
(SLBs) by the method of vesicle spreading, as described in
detail elsewhere [26]. Briefly, the surfaces were exposed for
30 min to small unilamellar vesicles, made from a mixture
of dioleoylphosphatidylcholine (DOPC) and dioleoylphos-
phatidylethanolamine-CAP-biotin (DOPE-CAP-b) (Avanti
Polar Lipids, Alabaster, AL, USA) at the desired molar ratio
(99.5 : 0.5 or 95 : 5) at a total concentration of 50 mg ml21 in
working buffer supplemented with 2 mM CaCl2 (VWR
International, Leuven, Belgium).
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Biotin-displaying surfaces were further functionalized for
studies of protein interactions with well-defined HS films,
as described in detail earlier [7]. Briefly, the surfaces were
first exposed to SAv, to form a SAv-monolayer, and then to
biotinylated HS (b-HS), to form a molecular film of HS that
is site-specifically attached through the reducing end to the
surface. This mode of attachment avoids any perturbation
of protein–HS interactions through chemical modifications
along the HS chain [27,28]. Sample concentrations and incu-
bation times were chosen such that binding either saturates
or equilibrates, unless otherwise stated.
2.5. Quartz crystal microbalance with dissipation
monitoring
Quartz crystal microbalance with dissipation monitoring
(QCM-D) measurements were performed, as previously
described [7]. QCM-D measures changes in frequency, Df,
and in dissipation, DD, of a quartz sensor upon interaction
of molecules with its surface. Measurements were performed
with a Q-Sense E4 system equipped with Flow Modules
(Biolin Scientific) with a flow rate of typically 10 ml min21
and at a working temperature of 248C. QCM-D data were
collected at six overtones (n ¼ 3, 5, 7, 9, 11, 13, corresponding
to resonance frequencies of approximately 15, 25, 35, 45,
55, 65 MHz). For the sake of simplicity, only changes in dis-
sipation and normalized frequency, Df ¼ Dfn/n, of the third
overtone (n ¼ 3) are presented. Any other overtone would
have provided comparable information.
Aviscoelasticmodel [29], implemented in the softwareQTM
(Diethelm Johannsmann, Clausthal University of Technology;
http://www2.pc.tu-clausthal.de/dj/software_en.shtml), was
used to quantify the thickness d and viscoelastic properties of
HS films from QCM-D data. Details of the fitting procedure
are described elsewhere [30]. We parametrized viscoelastic
properties in terms of the elastic and viscous compliances J0
and J00 at a reference frequency of f ¼ 15 MHz (i.e. close to
the resonance frequency at n ¼ 3). J0 and J00 are measures
for the softness of the film. The elastic compliance can also
be estimated directly from the QCM-D responses for the
film through the approximate relationship DD/(2Df ) ¼
4pnhlrl/r  J0, where hl ¼ 0.89 mPa.s and rl ¼ 1.0 g cm23 are
the viscosity and density of the aqueous bulk solution,
respectively, and r  1.0 g cm23 is the film density [31].
2.6. Fluorescence recovery after photobleaching
For fluorescence recovery after photobleaching (FRAP) assays,
cleaned glass coverslips were attached, using a bi-component
glue (Picodent, Wipperfu¨rth, Germany), to a custom-built
teflon holder, thus forming the bottom of four identical wells
with a volume of 50 ml each. All surface functionalization
steps were performed in still solution. To remove excess
sample after each incubation step, the content was diluted by
repeated addition of a twofold excess of working buffer and
removal of excess liquid until the concentration of the solubil-
ized sample, estimated from the extent of dilution, was below
10 ng ml21. Repeated aspiration and release ensured hom-
ogenization of the liquid volume at each dilution step. Care
was taken to keep the substrates wet at all times.FRAP measurements were performed with a confocal
laser scanning microscope (LSM 700, Zeiss, Germany)
using a laser with 555 nm wavelength, a plan-apochromat
63/1.4 oil immersion objective and a fully opened pinhole
(1 mm diameter). fl-SAv, attached to biotin-displaying SLBs,
was used as a fluorophore to report on the lateral mobility
of SAv-bound HS.
After acquiring three pre-bleach images, a circular region
with a radius of 10 mm in the centre of the imaged area was
bleached through exposure for approximately 20 s to high
laser intensity; approximately 80% bleaching in the centre
of the exposed area was achieved. The fluorescence recovery
due to lateral diffusion of bleached and unbleached fl-SAv
was monitored through acquisition of post-bleach images
over a period of typically 10 min.
The images acquired using this protocol were then analysed
by ‘time-resolved profile analysis’, a custom-made algorithm
[32] implemented in Matlab (MathWorks, MA, USA). Briefly,
each post-bleach fluorescence image was first corrected for
background fluorescence, spatial aberrations and intensity fluc-
tuations and then radially averaged. The radial intensity profiles
thus obtainedwere comparedwith numerical solutions of a dif-
fusion equation, where the first post-bleach image defined the
initial conditions for the diffusion process. A lateral diffusion
model with one mobile fraction and one immobile fraction
was found to reproduce our datawell. Thismodel has two inde-
pendent fitting parameters, namely the size and diffusion
constant of the mobile fraction. These were computed through
global minimization of the root-mean-square differences
between numerical predictions and all post-bleach profiles.3. Results
We tested the effect of several extracellular signalling mol-
ecules on HS model matrices, namely the a and g isoforms
of the chemokine CXCL12, the cytokine IFNg and the
growth factors FGF-2 and FGF-9. These were selected based
on their known affinity for HS and distinct structural features
(figure 1). All proteins bind HS more strongly, or at least as
strongly, as other glycosaminoglycans (GAGs) such as chon-
droitin sulfate or dermatan sulfate [23,25,38–41], suggesting
that HS serves as their natural ligand in HS-rich extracellular
matrices. CXCL12a forms homodimers through the associ-
ation of b-sheets upon binding to HS, with the known HS
binding site being located at the interface between the two
monomers (figure 1a). CXCL12g is distinct from CXCL12a
in that it features flexible C-terminal extensions that are also
involved in HS binding, and that it is not known to form
b-sheet dimers (figure 1b). IFNg is constitutively present as
a homodimer which features a very extended HS binding sur-
face on the flexible C-termini of the monomers (figure 1c).
The FGFs are more compact. FGF-2 has three distinct HS
binding sites (figure 1d ) that are separated from each other
by borders of negatively charged and hydrophobic residues.
FGF-9, by contrast, features only one HS binding site
(figure 1e). As HS matrix model, we employed films of HS
chains grafted with the reducing end to a protein-repellant
surface (figure 2a). QCM-D allows monitoring of HS film
assembly and protein binding as well as analysis of film
thickness and mechanical properties (figure 2). FRAP
allows for the lateral mobility of HS chains to be probed
(figure 3).
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FGF-2   
180° 180°
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Figure 1. Structures of soluble extracellular signalling proteins used in this study. Structures are surface plots, all drawn at the same scale (scale bar indicated
in (a)). Amino acids known to contribute to primary and secondary HS binding sites are shown in dark and light blue, respectively; the remaining protein surfaces
are coloured in grey, or in light brown for the second monomer in the structures of homodimers; the position of selected N or C terminals are marked with an arrow.
CXCL12a (a) is shown as a homodimer associated through b-sheets (PDB code: 1QG7, where missing residues were added as described in [17]) with its reported
HS-binding amino acids [15,17,33] and the first four amino acids, lacking in the CXCL12a(5–67) mutant, indicated (orange). CXCL12g (b) was constructed from a
CXCL12a monomer and the additional 30 amino acid long N-termini modelled as previously reported [23]. IFNg (c; PDB code: 1HIG [34]) is shown as a homodimer
with the C-termini (residues 120–143, absent in the structure) built as extended b-strands. FGF-2 (d; PDB code: 1FQ9 [35]) and FGF-9 (e; PDB code: 1IHK [36]) are
shown as monomers with their known HS binding sites, i.e. three sites for FGF-2 [37] and a single, extended site for FGF-9 [25].
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Our HS films present HS in an oriented manner and at con-
trolled density (figure 2a) [7]. Gold supports were first coated
with a monolayer of OEG exposing terminal biotin groups at
controlled surface density. A monolayer of SAv was then
formed and used to anchor HS through a biotin moiety that
was conjugated to the GAG’s reducing end [7]. Binding in
this orientation effectively reproduces the attachment of HS
to core proteins in HSPGs [42], and minimizes effects of
biotin conjugation and surface-confinement on protein bind-
ing. The SAv-on-OEG film inhibits non-specific protein
binding to the surface, i.e. measured responses are exclusively
because of specific interactions.
QCM-D was used to validate correct assembly of the
model surface and to characterize the effect of protein bind-
ing on HS films. The QCM-D response is sensitive to the
amount of adsorbed ligand (including coupled solvent),
with a negative frequency shift Df typically correlating with
a mass increase, and to mechanical properties, as well as
morphological features of the biomolecular film, typically
reflected in the dissipation shift DD [31].
QCM-D responses upon sequential incubation of OEG
monolayers with SAv and HS at saturation (figure 2b, curves
without symbols; at 6–21 min and 46–61 min, respectively, as
indicated by arrows on top of the graph) were consistent with
the formation of a relatively rigid SAv-monolayer (i.e. with
Df ¼ 223+1 Hz and a low dissipation shift, DD  0.3 
1026, at saturation) and a soft, hydrated HS layer (i.e. withDf ¼ 228.5+1.0 Hz and a high dissipation shift, DD ¼ 5.0+
0.2  1026, at saturation), respectively. As reported in our pre-
vious study [7], the frequency shift for such an HS film
(henceforward called high-density HS film) corresponds to an
arealmass density of 35.5+2.2 ng cm22, and to awater content
of 96.9+0.5%. In this earlier work, we had also estimated
the mean distance between adjacent HS anchor sites to be
5 nm, consistent with the dimensions of SAv, and the mean
length of the surface-bound HS chains to be 20 monosac-
charides (or 10 nm); in this regard, we note that the mean
length of surface-bound b-HS chains is shorter than the mean
length in the solution from which they were bound, because
shorter chains bind preferentially [7]. In essence these numbers
indicate that, while there is plenty of space for small proteins to
bind into the HS films, the pendant HS chains are long enough
to make contact with their neighbours and cover the whole
surface area.3.2. Effect of CXCL12a binding on HS films
Exposure of the chemokine CXCL12a at a concentration of
0.64 mM to the high-density HS film generated a negative fre-
quency shift (29+1 Hz; figure 2b, blue curve without
symbols, 74 to 90 min), confirming CXCL12a binding. The con-
comitant change in dissipation was pronounced and negative
(23.8+0.2  1026; figure 2b, red curve without symbols).
Such a QCM-D response provides a strong indication that the
chemokine rigidifies the HS film. Quantitative analysis of the
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Figure 2. Design of HS films and effect of CXCL12a binding. (a) Schematic representation with the relative sizes of all molecules approximately drawn to scale. HS
is biotinylated at the reducing end for oriented and specific immobilization on streptavidin (SAv). SAv is specifically bound to a gold-supported monolayer of thio-
lated oligo(ethylene glycol) (OEG) exposing terminal biotin. (b) Surface functionalization and CXCL12a binding followed by QCM-D (frequency shifts, Df, dissipation
shifts, DD). Start and duration of incubation steps with different samples are indicated by an arrow; during all other times, the surface was exposed to buffer. SAv
was first incubated at 1mg ml21 and then at 20 mg ml21 and responses are consistent with the formation of a dense protein monolayer [7]. b-HS was incubated
either at 50 mg ml21 to saturation (‘high-density HS films’, curves without symbols) or at 1 mg ml21 for 15 min to reach about 30% of maximal coverage (‘low-
density HS films’, curves with square symbols). CXCL12a, incubated at 0.64 mM, induced dissipation decreases for both HS densities, indicating rigidification of the
hydrated HS film upon chemokine binding. (c) Elastic compliance J0, viscous compliance J00 and thickness of HS films obtained from QCM-D data for high-density HS
films, bare and with CXCL12a at binding equilibrium. Data correspond to mean and standard error of the mean from three independent experiments. All parameters
decreased upon CXCL12a incubation, confirming film rigidification and compaction.
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in the elastic compliance J0 and the viscous compliance J00 upon
CXCL12a binding (figure 2c). J0 and J00 are physical parameters
(elastic and viscous contributions, respectively) related to film
softness, and their decrease thus confirms film rigidifica-
tion. This analysis also revealed that the protein induces a
moderate decrease in film thickness (figure 2c). Upon sub-
sequent rinsing in buffer, frequency and dissipation increased
slowly, but did not return to the level of the virgin HS film
(figure 2b, curves without symbols; from 89 min), demon-
strating that some, but not all CXCL12a is released over
experimentally accessible time scales, and that the HS film
partially recovers its original morphology.To test if the protein-induced morphological changes
depend on HS surface density, we repeated the QCM-D
assay at reduced HS surface coverage (figure 2b, curves
with square symbols). To this end, b-HS was incubated at a
lower solution concentration (1 mg ml21) and binding was
interrupted after 15 min (figure 2b, 46 to 61 min). The fre-
quency shift for HS (28+1 Hz) in this case (henceforward
called low-density HS film) corresponds to an areal mass
density of 12.0+0.5 ng cm22 and an average distance
between adjacent HS anchors of about 10 nm, according to
previously reported estimates [7]. It is thus likely that most
HS chains can make contacts with their neighbours even
for low-density HS chains. CXCL12a induced a clear (albeit
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Lateral mobility of fl-SAv was assessed in the absence of b-HS, after incubation with b-HS at saturation, after 15 min incubation of the HS film with chemokines (in
the presence of 0.64 mM chemokines in solution) and after regeneration of the HS film by 2 M GuHCl. Data correspond to mean and standard error of the mean for
three independent experiments.
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i.e. film rigidification also occurred on low-density HS films.3.3. Effect of CXCL12a binding on HS chain mobility
We hypothesized that the rigidification and thinning of HS
films is due to cross-linking of HS chains by the chemokine.
However, an alternative explanation could be that indivi-
dual HS chains wrap around CXCL12a molecules, thereby
stiffening the film and reducing the film thickness without
generating any inter-chain cross-links. To distinguish between
these two scenarios, we tested how the chemokine affects the
lateral mobility of HS chains.To this end, we used a modified model surface in which
the gold-supported OEG monolayer was replaced by a silica-
or glass-supported lipid bilayer (SLB; figure 3a). The oriented
immobilization of HS at controlled densities is retained on
these surfaces and the SAv-on-SLB film is also effectively pas-
sivating against non-specific binding of proteins [7]. SLBs are
distinct, however, in that they provide a fluid surface on
which SAv, and the SAv-bound b-HS, have the freedom to
move laterally (schematically shown in figure 3a).
The lateral mobility was probed by FRAP, using fluores-
cently labelled SAv (fl-SAv) as b-HS anchors. In this
method, a limited surface area is rapidly bleached and diffu-
sion of fluorescent molecules into (and bleached molecules
out of) the bleached area is subsequently monitored.
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(figure 3b). The fraction of biotinylated lipids used to form
SLBs was adjusted to 0.5% such that incubation of fl-SAv at
saturation (figure 3b, 10 to 20 min) led to a partial protein
monolayer, in which the SAv molecules diffused freely, i.e.
without being appreciably hindered by two-dimensional
crowding. The fluorescent label did not induce any non-
specific binding of CXCL12a or HS (figure 3b, 29 to 37 min
and 44 to 51 min, respectively). The shifts in frequency
(29+ 1 Hz) and dissipation (2+ 0.2  1026) for incubation
of b-HS at saturation (figure 3b, 58 to 68 min) were compar-
able with the low-density HS film shown in figure 2b.
Moreover, the QCM-D responses upon subsequent binding
of CXCL12a (figure 3b, 92 to 105 min) were also similar to
those observed in figure 2b. This indicates that the FRAP
measurements can be directly correlated with QCM-D
measurements on low-density HS films.
The representative fluorescence micrographs in figure 3c
demonstrate close-to-complete recovery of virgin b-HS films
within 100 s, confirming that fl-SAv with HS is indeed laterally
mobile, as desired. By contrast, the bleached spot remained
clearly visible after 100 s when CXCL12a was added to the
HS film. Radially averaged fluorescence intensity profiles
were computed from time-lapse series of micrographs after
photobleaching, and analysed to quantify lateral mobility. To
this end, the pool of fl-SAv was assumed to be distributed in
two distinct fractions, one immobile and the other laterally
mobile with a given diffusion constant. The size of the
mobile fraction and its diffusion constant are shown in
figure 3d,e. These quantitative results confirm that virtually
all (i.e.  95%) fl-SAv in a virgin SAv-monolayer was mobile,
and that the mobility was unaffected by the presence of
b-HS. In the presence of CXCL12a, 40% of the fl-SAv became
effectively immobilized, and additionally, the diffusion con-
stant of the retained mobile fraction was strongly reduced
(by 45%). These data provide evidence that CXCL12a impedes
lateralmotion of HS and its fl-SAv anchor, andwe propose that
this immobilization is the consequence of CXCL12a-mediated
HS cross-linking.
After treatment with 2 M GuHCl, which we know effec-
tively releases all CXCL12a from HS while keeping the HS
film intact [7], the mobile fraction and its diffusion constant
largely returned to the values observed for a virgin HS film.
This confirms that HS mobility is restored upon chemokine
release, i.e. the cross-linking is reversible and requires
the presence of the chemokine. The mobile fraction though
remained marginally reduced, indicating that a small fraction
of fl-SAv remains permanently immobile upon GuHCl treat-
ment. Most probably, the lack of complete regeneration is
due to a weak yet irreversible perturbation of the fl-SAv film
by GuHCl: detailed inspection of the fluorescent micrographs
after GuHCl treatment revealed bright spots that we believe
are fl-SAv aggregates.
3.4. Effect of CXCL12a mutations on HS cross-linking
CXCL12a is known to form b-sheet dimers (figure 1a) upon
binding to HS [15]. To test if this oligomerization is involved
in HS cross-linking, we additionally tested two CXCL12a
constructs with point mutations that leave the ternary struc-
ture of CXCL12a essentially intact, but alter the ability of
the protein to form b-sheet dimers: L36C/A65C mutations
result in inter-molecular disulfide bonds and formation of a‘locked dimer’ [22] while I55C/L58C mutations promote an
intra-molecular disulfide bond and formation of a ‘partial
monomer’ with a reduced propensity to form dimers [21].
We tested the effect of binding of these constructs to low-
and high-density HS films by QCM-D, and HS mobility in
low-density HS films by FRAP. As with the wild-type, both
mutants bound to HS films (figure 4a, blue curves), but not
to the supporting SAv-monolayer (figure 4a, grey curves
with triangle symbols). Binding to HS was distinct, however,
with regard to the magnitude of the frequency shift at equili-
brium and reversibility upon elution in buffer. The locked
dimer exhibited enhanced and more stable binding, whereas
binding was reduced and less stable for the partial monomer,
as compared with native CXCL12a. These systematic vari-
ations reflect the importance of CXCL12a dimerization in
stabilizing the interaction between the protein and HS [21].
Interestingly, both mutants also generated pronounced
decreases in dissipation (figure 4a, red curves) upon binding
to HS, albeit with different magnitudes. Parametric plots
of the DD/2Df ratio as a function of 2Df are shown in
figure 4b. At a given HS density, the curves were very similar
for all three protein constructs, except at the highest magni-
tudes of Df. For thin films, the DD/2Df ratio is proportional
to the elastic compliance J0 [31] and thus a simple relative
measure for softness, whereas 2Df is a relative measure for
the protein surface density. The plots illustrate that the softness
of HS films reduces only marginally as the HS grafting density
increases duringHS film formation (i.e. from2Df ¼ 0 to 28.5+
1 Hz), and that subsequent protein binding (cf. larger values of
2Df ) reduces the softness drastically and in a coverage-depen-
dent manner. The fact that the DD/2Df versus 2Df curves for
protein binding are superimposed indicates that the mechan-
ical properties (and hence the morphologies) of the HS films
are comparable for a givenHS surface density and protein con-
centration in the film, irrespective of the quaternary state of the
employed protein. This implies that the differences in the mag-
nitude of Df and DD at equilibrium are entirely because of
differences in the affinity (i.e. the adsorbed amounts), but
that the intrinsic propensity of CXCL12a to cross-link HS
does not depend on protein oligomerization.
Complementary FRAP assays revealed that the partial
monomer and locked dimer can effectively reduce the mobile
fraction (figure 4c) and its diffusion constant (figure 4d ), con-
firming that all CXCL12a constructs can indeed cross-link
HS. However, an appreciable reduction in mobility for the par-
tial monomer could only be observed after increasing the
protein solution concentration (by sixfold). Moreover, after
elution of residual partial monomer from the bulk solution
with working buffer, the mobile fraction and its diffusion con-
stant returned close to the level of a virgin HS film, whereas
both parameters remained unaffected for the locked dimer.
This demonstrates that an efficient cross-linking of the HS
film requires a minimal protein concentration. Taken together,
we conclude that the HS-induced CXCL12a dimerization
[21,22] enhances protein binding, but that this dimeric struc-
ture is dispensable for HS cross-linking if the reduced affinity
is compensated by an increased protein solution concentration.
CXCL12a mutants lacking the N-terminal lysine residue
have been reported to display reduced affinity for HS based
on surface plasmon resonance data [15,33], while nuclear mag-
netic resonance (NMR) analysis found no direct evidence of
interaction with heparin-derived oligosaccharides [19,33]. We
hypothesized that this amino acid, which forms the end of a
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Figure 4. Dimerization and N-terminal lysine are dispensable for HS cross-linking. (a) QCM-D data for the binding of selected CXCL12a constructs to low-density
(curves with square symbols) and high-density (curves without symbols) HS films on SAv on OEG monolayers. As in figure 2b, Df and DD are shown relative to
SAv-coated surfaces before b-HS binding, yet b-HS binding is not explicitly shown. All samples were injected at 0 min and a concentration of 0.64 mM monomer
equivalents; arrowheads indicate the start of rinsing in working buffer. Protein binding was also tested on SAv-monolayers without HS (grey curves with triangle
symbols; only shown for Df ) to confirm absence of non-specific binding. Frequency shifts at equilibrium and unbinding curves after rinsing differed between
CXCL12a constructs, indicating that their binding affinities are distinct. However, all constructs induced dissipation decreases on low- and high-density films, indi-
cating HS film rigidification. (b) Parametric plot of DD/2Df for the protein-loaded HS film (a relative measure for film softness) versus –Df for protein binding (a
relative measure for protein surface density) for the binding data on low-density (left) and high-density (right) HS films displayed in (a) (with colour code as
indicated). The curves largely superpose for all four CXCL12a constructs, indicating that, for a given combination of HS and protein surface densities, the mechanical
properties of the HS films are comparable. Representative data for HS film formation (grey) is given for comparison. (c,d) Mobile fractions and their diffusion
constants of b-HS (bound to fl-SAv on SLBs) before incubation with CXCL12a constructs, after incubation with the proteins at equilibrium (native CXCL12a,
CXCL12a(5–67) and locked dimer at 0.64 mM monomer equivalents, partial monomer at 3.8 mM), and after elution of respective protein from the solution
phase, as indicated. The fluorescent label of fl-SAv was confirmed by QCM-D not to induce any measurable non-specific binding of any of the CXCL12a constructs
(not shown). The mobility data confirm that all CXCL12a constructs can cross-link HS.
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other amino acids known to be involved in HS binding [17],
may be important for cross-linking. To test this, we studiedan additional construct with a truncated amino acid sequence,
i.e. a mutant that lacked the four N-terminal amino acids
(CXCL12a(5–67); figure 1a). The magnitudes of the frequency
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Figure 5. CXCL12a binding to and rigidification of films of oligomeric HS. (a)
CXCL12a binding to monolayers of b-HS oligosaccharides of different lengths
(as indicated; dp ¼ degree of polymerization), immobilized on a SAv-mono-
layer on OEG (figure 2) was monitored by QCM-D to test the minimal length
needed for the chemokine to bind and to cross-link HS. Injection of b-HS
oligosaccharides (at 50 mg ml21; left panels) and CXCL12a (at 0.64 mM;
right panels) started at 0 min, and arrowheads indicate the start of rinsing
with working buffer. Clear binding of CXCL12a is only observed for HS of
dp8 (Df ¼24 Hz) and larger, indicating that a hexasaccharide is not suffi-
ciently long for protein binding. Pronounced dissipation decreases for HS as
small as dp8 indicate that even films of oligomeric HS are rigidified. (b,c)
Mobile fractions and their diffusion constants of b-HS oligosaccharides
(bound to fl-SAv on SLBs) either bare or in the presence of 0.64 mM
CXCL12a, as indicated. The moderate reduction in dp12 mobility suggests
that oligosacharides can be cross-linked into relatively small clusters by
CXCL12a.
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on high-density HS films and slightly reduced on low-density
HS films (figure 4a), consistent with a rather weak contribution
of the N-terminal lysine to protein binding. Importantly, the
mutant also showed a negative dissipation shift, and the
DD/2Df versus2Df curves for CXCL12a(5–67) and native
CXCL12a at a given HS surface density (figure 4b) were indis-
tinguishable. Moreover, FRAP results (figure 4c,d) confirmed
that the mutation does not affect HS mobility. Taken together,
these data indicate that the N-terminus is also dispensable for
cross-linking, which is presumably consistent with its modest
and/or transient interaction with HS [15,17,33].
3.5. Effect of CXCL12a on HS oligomers
Having established that CXCL12a cross-links HS, we next
tested if there is a minimal length of HS chains required for
cross-linking. CXCL12a binding to HS oligosaccharides of
different size was analysed by QCM-D to determine the mini-
mum number of saccharides necessary for CXCL12a binding
and cross-linking (figure 5a). No response was observed on
hexasaccharides (dp6), while clear binding was present on
dp8, dp10 and dp12, confirming that an octasaccharide but
not a hexasaccharide is sufficient for efficient binding, in agree-
ment with the literature [15]. The dissipation decreased only
slightly yet significantly (20.1  1026) for dp8, while films of
dp10 and dp12 showed pronounced dissipation decreases
upon CXCL12a binding. Clearly, the chemokine induced a
rigidification of the oligosaccharide HS layers, suggesting
that even rather short HS chains can be cross-linked.
Consistent with this interpretation, FRAP measurements
on dp12 revealed significant decreases in the mobile fraction
and its diffusion constant with CXCL12a (figure 5b,c). No
significant effect was observed with dp6, as expected,
demonstrating specificity of the assay. The effect of
CXCL12a on the mobility of dp12 was, however, rather
weak. This indicates that the oligosaccharides assemble into
relatively small clusters with largely retained lateral mobility.
In other words, longer HS chains are required for a sufficient
amount of CXCL12a to bind to each chain and thus to induce
effective cross-linking of many HS chains.
3.6. Effect of other HS-binding proteins on HS films
To test whether HS-cross-linking is unique to CXCL12a, we
extended our study and systematically investigated the effect
of several other HS-binding proteins, namely CXCL12g,
IFNg, FGF-2 and FGF-9, on high- and low-density HS surfaces
by QCM-D, and on low-density HS surfaces by FRAP
(figure 6). The structures of all tested proteins are known
and HS binding sites have been identified [23,34,36,37,43]
(figure 1b–e). As expected, none of the proteins exhibited any
significant non-specific binding to the SAv-monolayer
(figure 6a, grey curves with triangle symbols).
Compared with CXCL12a (figure 1a), CXCL12g
(figure 1b) features 30 additional amino acids at the C-termi-
nus, which are known to have HS-binding activity and
enhance the affinity of CXCL12 for HS: dissociation constants
KD of 200 nM and 1.5 nM have been reported for the a and g
isoforms, respectively [23]. Indeed, CXCL12g bound more
stably and more rapidly than CXCL12a (figures 6a and 4a,
respectively, blue curves). The decrease in dissipation for
CXCL12g was pronounced at low and high HS coverage(figure 6a, red curves). The DD/2Df versus 2Df plots
(figure 6b) confirm that this protein also has a strong propen-
sity to rigidify the HS film. In these plots, differences between
CXCL12g and CXCL12a were small, albeit significant com-
pared with the variations between CXCL12a and its
mutants (figure 4b), suggesting that there are subtle differ-
ences in the morphology of the protein-loaded HS films.
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Figure 6. Correlation between structure and HS cross-linking propensity of HS-binding proteins. (a) QCM-D data for binding of proteins to HS films are displayed
analogous to figure 4a. CXCL12g, as CXCL12a, induced strong negative shifts in dissipation irrespective of HS film density; FGF-2, but not FGF-9, induced negative
dissipation shifts irrespective of HS film density; for IFNg, the dissipation decreased only on high-density HS films, indicating distinct, protein-specific degrees of HS
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Mobile fractions and their diffusion constants of b-HS (bound to fl-SAv on SLBs at low surface density) either bare or in the presence of CXCL12g, FGF-2 or FGF-9, as
indicated. (e,f ) Mobile fractions and their diffusion constants of b-HS (bound to fl-SAv on SLBs at low surface density (left graphs) and high surface density (right
graphs)) either bare or in the presence of IFNg, as indicated. The fluorescent label of fl-SAv was confirmed by QCM-D not to induce any measurable non-specific
binding of any of the HS-binding proteins (not shown). Protein concentrations used throughout were 0.43 mM for CXCL12g, 0.29 mM for IFNg, 0.28 mM for FGF-2
and 0.17 mM for FGF-9. The mobility and rigidification data correlate, confirming that FGF-2 is a potent cross-linker whereas FGF-9 does not cross-link, that CXCL12g
cross-links HS film similarly to CXCL12a locked dimer, and that IFNg is a rather poor cross-linker.
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its diffusion constant (figure 6c,d) somewhat more strongly
than native CXCL12a, i.e. to a similar extent as the locked
dimer of CXCL12a (figure 4c,d). We conclude that
CXCL12g is also a potent HS cross-linker and that this
potency is enhanced by the HS binding stability.
IFNg is a homodimeric cytokine known to strongly inter-
act with HS (KD  1 nM [39]). The known HS binding site is
located at the C terminus and the two C termini in the homo-
dimer are spatially separated (figure 1c). At present, it is not
clear, if the two binding loci bind to a single or to two distinct
HS chains. IFNg readily bound to the HS films and binding
was very stable as shown by the QCM-D frequency response
(figure 6a). In high-density HS films, IFNg induced a nega-
tive shift in dissipation (figure 6a) albeit with a reduced
magnitude compared with CXCL12a (figure 4a). However,
IFNg generated a slight increase in dissipation in low-density
HS films. FRAP (figure 6e,f, left plots) revealed that IFNg
induces only moderate reductions in the mobile fraction of
HS (by 15%) and in the diffusion coefficient of this mobile
fraction (by 25%). The lack of dissipation decrease and the
weak reduction in HS mobility thus correlate, and indicate
that IFNg does not cross-link HS strongly, at least at low sur-
face density. Under these conditions, the two HS binding
sites on the IFNg homodimer apparently bind within a
single HS chain (intra-HS-chain bond).
To test if the decrease in dissipation at high HS surface
density (figure 4a) is an indicator for the formation of inter-
HS-chain bonds by IFNg when HS chains are densely
packed, we performed additional FRAP measurements at
high HS surface densities (figure 6e,f, right plots). To this
end, the fraction of biotinylated lipids used to form the SLB
was increased (from 0.5 to 5%) to enable formation of a
dense fl-SAv-monolayer. Under these conditions, the lateral
mobility of the bare HS films was largely retained (i.e. the
mobile fraction was only slightly reduced, to 90%) although
crowding of fl-SAv entailed a marked reduction of the diffu-
sion constant (from 2 mm2 s21 to 0.5 mm2 s21). Interestingly,
the mobile fraction as well as its diffusion constant decreased
only weakly in the presence of IFNg (by 12% and 20%,
respectively). This indicates that the IFNg homodimer prefers
to form intra-HS rather than inter-HS-chain bonds even
at high HS concentrations, and supports the previously
proposed model in which IFNg binds to two adjacent N-sul-
fated domains along a single HS chain [44].
FGF-2 and FGF-9 were selected because of their well-
characterized HS binding sites (figure 1d,e). FGF-2 has three
HS binding sites, of which two are located on the same face
and the third on the opposite face of the protein [37,43,45,46].
By contrast, only one (rather extended) HS binding site has
been identified for FGF-9 [25]. FGF-2 and FGF-9 were reported
to have affinities of 10 and 620 nM, respectively, to heparin dp8
(i.e. a representative of high-affinity binding sites on HS)
[25,47]. Both FGFs bound readily to HS films (figure 6a), as
expected. The frequency shifts on high-density HS films
exceeded those observed for the previously investigated
chemokines (figures 4 and 6), indicating extensive binding.
FGF-2 generated pronounced decreases in dissipation for
high-density and low-density HS films. By stark contrast, the
dissipation remained largely unchanged and increased drasti-
cally, respectively, for FGF-9. This contrast is also apparent in
the DD/2Df versus 2Df plots (figure 6b), where the curves
for FGF-9 are located above the curves for FGF-2 irrespectiveof the HS surface density, thus indicating that FGF-2 is more
potent in rigidifying HS films. FRAP revealed a drastic
reduction (by 80%) in the mobile fraction with FGF-2
(figure 6c), i.e. this protein essentially immobilized HS.
FGF-9, on the other hand, did not affect the mobile fraction at
all (figure 6c) and the diffusion constant of the mobile fraction
was only weakly affected (figure 6d).
Clearly, FGF-2, but not FGF-9, has a strong propensity to
cross-link and to rigidify HS films. In the light of the distinct
structural features of these two growth factors, we propose
that FGF-2 cross-links HS by accommodating at least two
different chains simultaneously in its multiple HS binding
sites, whereas only one HS chain at a time can bind to the
extended binding site on FGF-9. The results with FGFs high-
light that not all HS-binding proteins cross-link HS and
that the cross-linking propensity can vary distinctly among
proteins of the same family.4. Discussion
4.1. What are the molecular mechanisms behind HS
cross-linking?
One may argue that a protein with an HS-binding surface
large enough to accommodate more than one HS chain
should be able to cross-link HS. Yet, we found the extension
of the HS-binding surface alone to be a poor predictor of a
protein’s cross-linking propensity. This is illustrated by the
limited cross-linking propensity of the IFNg homodimer
(figure 6), and also by the negligible effects of the elongated
C-terminal of CXCL12g, compared with CXCL12a, on
HS film rigidification and cross-linking (figures 4 and 6).
Apparently, the formation of multiple bonds with the
same HS chain is more favourable in these cases than the
inter-connection of several distinct HS chains.
FGF-2, by contrast, exhibited strong cross-linking activity
(figure 6). A detailed inspection of the protein’s surface reveals
that the threeHS-binding patches containing basic amino acids
are separated from each other by acidic and hydrophobic
amino acids. Such HS-repelling rims are not present in any of
the other proteins tested. From the correlation with our exper-
imental data, we thus propose multiple HS-binding patches
separated by HS-repelling borders as a distinct structural
feature conducive to HS cross-linking.
Mutation of the primary binding site reduces binding of
FGF-2 to HS substantially [48], i.e. the affinities of the second-
ary HS binding sites on FGF-2 are rather weak. Yet, FGF-2
apparently is a potent HS cross-linker. This effect is not sur-
prising if one takes into consideration that, once FGF is
sequestered into the matrix through its primary high-affinity
binding site, the local concentration in HS is high such that
even weak interactions can occur frequently. Thus, the
example of FGF-2 illustrates how rather weak secondary
binding sites can fulfil functions.
CXCL12 is also a potent HS cross-linker (figures 4–6), yet
the molecular mechanism of cross-linking must be different
since this protein does not feature several clearly separated
binding sites. It is instructive to consider the quaternary struc-
ture of this protein. Upon HS binding, CXCL12 readily forms
homodimers through the association of b-sheets [15], but our
testswith partialmonomer and locked dimer (figure 4) demon-
strated that this ‘b-sheet’ dimer is not directly involved in HS
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that CXCL12a can form another homodimer through the
association of two N-termini, analogous to what is commonly
observed for chemokines of the CC family [50], although the
functional significance of the ‘N-terminal’ dimer has so far
remained unclear.
We propose that b-sheet and N-terminal dimers coexist in
the HS matrix, potentially forming dimers of dimers. In this
scenario, the two dimerization mechanisms would have dis-
tinct functions, i.e. dimerization through b-sheets enhances
the affinity of the protein for HS whereas dimerization
through N-termini induces HS cross-linking. Our experimen-
tal data are fully consistent with such a scenario. In
particular, arginines at positions 8 and 12 were found to be
involved in the formation of the N-terminal dimer [49].
These are present in all mutants (including the truncated
CXCL12a(5–67) form), and it is thus not surprising that all
our CXCL12a constructs exhibited a similar propensity to
rigidify and cross-link HS films once the differences in
affinity were adjusted for (figure 4b–d). Moreover, an
N-terminal dimer can also readily cross-link short HS oligo-
saccharides (figure 5), whereas such an effect would be
difficult to explain with b-sheet dimers alone: in the current
binding model, dp8 is just long enough to fit the HS-binding
interface in the b-sheet dimer [19]; it would be conceivable
that a single dp8 binds two b-sheet dimers (i.e. one on each
face of the oligosaccharide), but not the opposite. Future
studies with other CXCL12a mutants should be useful to
test if the arginines at positions 8 and 12 are indeed crucial
for dimerization-mediated cross-linking and how HS binding
[19,33] and CXCL12a oligomerization interplay to promote
cross-linking. In this regard, it is notable that many chemo-
kines form oligomers, when free in solution or upon
binding to GAGs [51]. It will thus also be interesting to inves-
tigate how the oligomerization of other chemokines correlates
with their propensity for cross-linking GAGs.4.2. The methodological approach presented in this
study is novel
HS films as model matrices present HS at controlled orien-
tation and lateral mobility and at tuneable surface density,
thus enabling supramolecular interaction studies under
well-defined conditions. The two characterization techniques,
QCM-D and FRAP, provide complementary information and
together enable identification of the protein’s binding and
cross-linking activity. Specifically, QCM-D provides infor-
mation about binding kinetics, and about HS/protein film
morphology (thickness) and rigidity, whereas FRAP enables
quantification of the lateral mobility of HS chains. The
assay does not require any labelling of the protein and is
thus broadly applicable to assess the propensity of proteins
to cross-link HS and other GAGs. In particular, some extra-
cellular signalling proteins are known to bind several types
of GAGs (e.g. CXCL12g [23,38] or IFNg [38–40]) and it will
thus be interesting to probe if the propensity of a given
protein to cross-link is specific to a particular GAG type.
GAG-on-chip devices are increasingly used to probe the
interaction of GAGs with proteins. On such devices, the
extent of protein-mediated GAG cross-linking will depend
sensitively on the presentation and surface density of
GAGs. As a consequence, the binding behaviour of proteinsmay also vary strongly, calling for care in the interpretation
of the read out and comparison of data between different
GAG-on-chip-based assays. The method developed here
should be very useful to evaluate how GAG presentation
and surface density affect binding.4.3. What is the functional relevance of HS cross-linking
by extracellular signalling proteins?
Cross-linking ofHS requires the spatial proximity ofHS chains.
This criterion was met on average in our well-defined model
matrices within the range of HS surface densities employed.
Based on the typical length ofHS chains and the typical density
of HS-bearing proteoglycans (PGs), Yanagishita & Hascall [14]
estimated that the ensemble of HS chains on cells can readily
explore the entire cell surface. This implies that neighbouring
HS chains can meet, and HS cross-linking thus may also be a
frequent phenomenon at the cell surface and in extracellular
matrix. The distribution of HS, however, may not be homo-
geneous across the cell surface [52] and may vary across cell
types and states. This implies that the local HS density can
vary over a large range, and that cross-linkingmay be confined
to specific locations. It is thus possible that HS cross-linking is
spatio-temporally controlled through the expression of HS
and the sequestration of chemokines or growth factors in the
course of specific biological processes (e.g. angiogenesis [53],
inflammation [54], cell proliferation [6,47,55]). This may have
consequences at different levels.
On the level of the matrix, the proteins can promote
changes in structure that parallel their signalling activity. The
ensuing changes in physical properties of peri- and extracellu-
lar matrices, such as permeability, rigidity or thickness, may
elicit a range of additional cellular responses. For example, a
reduction in the thickness of pericellular coats may facilitate
intercellular contacts through membrane-bound cell adhesion
receptors/ligands [56], or the cross-linking of HS displayed
by two distinct pericellular coats could be important in the
initial stage of cell–cell adhesion. Moreover, changes in the
rigidity of the cellular glycocalyx through HS cross-linking
may provide a physical cue that guides the behaviour of cells.
On the local scale, cross-linking of HS could promote clus-
tering of cell-surface PGs to which the HS chains are attached,
thereby activating signalling. Clustering of the HSPG synde-
can-4, for example, is important for the binding to and
activation of protein kinases which ultimately determine the
assembly of focal adhesions and the organization of the actin
cytoskeleton [57]. In this regard, it has been demonstrated
that a syndecan-4 dimer requires a minimum of four HS
chains to be functional, whereas a mutated form of synde-
can-4 with a single HS chain was not functional unless a
cluster of multiple syndecan-4 dimers was formed. This
suggests that multiple HS chainsmust associate in the presence
of a ligand, to form a signalling unit [58]. In this scenario, HS-
cross-linking proteins would elicit signalling activity in a way
that has thus far not been appreciated. Moreover, the inter-
action between FGFs and syndecans has been demonstrated
to promote their clustering, activation of protein kinase Ca,
translocation to cholesterol-rich membrane domains and even-
tually internalization and transfer of FGF-2 to the nucleus
[59–62]. Thus, ligands that do not cause cross-linking of HS
chains, such as IFNg and FGF-9, may not be able to activate
these parallel, HS-specific signalling pathways. A further
rsob.royalsocietypublishing.org
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cross-linkHS chains on syndecans is the formation of exosomes
[63]. Future studies comparing the effect of proteins that cross-
link HS (e.g. FGF-2, CXCL12a or CXCL12g) with those that
do not (e.g. IFNg or FGF-9) would provide a direct test if HS
cross-linking is important for exosome formation and other
HS-specific signalling pathways. Last but not least, the proteins
themselves would also be affected by HS cross-linking, in that
the attachment through multiple binding sites reduces their
mobility. This may contribute, for example, to the substantial
fraction of FGF-2 that is observed to undergo confined, rather
than diffusive motion in pericellular matrix [52].en
Biol.5:1500465. Conclusion
In summary,we have demonstrated that extracellular signalling
proteins can cross-link GAGs and propose that several binding
sites, well separated either through GAG-repellent borders on
the protein’s surface (e.g. FGF-2) or through spatial separation
in quaternary protein structures (e.g. N-terminal CXCL12
dimers), are required for GAG cross-linking. This prediction
can now readily be tested with other GAG-binding proteins
using the here-presented GAG cross-linking assay. The ability
of extracellular signalling proteins to influence matrix organiz-
ation and physico-chemical properties implies that the
functions of these proteins may not simply be confined to theactivation of cognate cellular receptors. This may have
far-reaching implications for cell–cell and cell–matrix com-
munication, and our predictions can be tested in future cell
and in vivo assays.
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